December 1998 in “福井大学教育学部紀要 第4部 教育科学” HA-P5 effectively treats acne without causing side effects seen in other treatments.
The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
January 2012 in “Курский научно-практический вестник "Человек и его здоровье"” 5-alpha-reductase inhibitors can effectively treat benign prostatic hyperplasia.
2 citations
,
April 2016 in “Más dermatología” The supplement with Serenoa repens and Pygeum africanum significantly increased active hair growth and decreased rest phase hair in post-menopausal women with hair loss, with only mild digestive side effects.
May 2015 in “Journal of The American Academy of Dermatology” 5% minoxidil foam helps women with thinning hair.
November 2017 in “JAMA internal medicine” Women also use 5α-reductase inhibitors, and their effects differ from men.
12 citations
,
March 2016 in “Life Sciences” The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.
August 2013 in “Hospital Pharmacy” Certain medications can cause serious side effects, including skin reactions, stroke, muscle disorders, tongue swelling, hair loss in women, and liver failure.
June 2020 in “Journal of clinical and investigative dermatology” Nourkrin® Woman with Marilex® improves hair growth, appearance, and confidence in women with hair loss.
5 citations
,
December 2014 in “Medicine and Pharmacy Reports” Ciproterone acetate improves hair regrowth and acne in most female patients.
2 citations
,
February 2023 in “F&S Reports” Elagolix did not effectively treat polycystic ovary syndrome.
January 2004 in “Drug Development and Industrial Pharmacy” GI197111X is best dissolved in Capmul MCM for trials.
April 2016 in “Journal of Investigative Dermatology” Phenylephrine may help prevent hair loss from pulling on the hair roots.
July 2023 in “Journal of Clinical Medicine” Tirzepatide might help manage PCOS in obese patients but needs more research to confirm safety and effectiveness.
8 citations
,
September 2021 in “EMBO Molecular Medicine” A new small peptide may help hair growth by activating a specific receptor and should be tested in humans.
3 citations
,
May 2017 in “Bioorganic & medicinal chemistry letters” New compounds were made that are promising for prostate cancer therapy.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
A mix of Polygonatum sibiricum and Nelumbinis semen may ease menopause symptoms with fewer side effects.
7 citations
,
August 2019 in “Bioorganic & medicinal chemistry” Analog 23 is a promising compound for prostate cancer treatment.
FemmeBalance supplement significantly improved PMS symptoms in women.
These medications for BPH have known risks and may have new side effects.
1 citations
,
September 2025 in “International Journal of Drug Delivery Technology” Ecklonia cava improves the effectiveness of Diane-35 in managing PCOS symptoms.
18 citations
,
December 2005 in “Journal of Medicinal Chemistry” A brominated phenoxy compound effectively inhibits a human enzyme and shows potential for clinical use.
13 citations
,
August 2007 in “Bioorganic & medicinal chemistry letters” A new compound effectively inhibits human 5α-reductase 1.
16 citations
,
November 2018 in “Medicinal Chemistry” The compound GD-23 may reduce anxiety like diazepam by targeting the TSPO receptor.
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.
58 citations
,
January 2015 in “Journal of the American Academy of Dermatology” Pioglitazone may help treat lichen planopilaris, but more research is needed.
GLP-1 receptor agonists for weight loss may cause hair loss, especially in women.
46 citations
,
July 2010 in “Advances in Therapy” SPET-085 effectively inhibits an enzyme linked to prostate issues, similar to finasteride.
3 citations
,
March 2017 in “Regulatory toxicology and pharmacology” Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.